Aberdeen Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-84,822
Closed -$15.6M 1075
2021
Q2
$15.6M Sell
84,822
-5,150
-6% -$884K 0.03% 401
2021
Q1
$13.8M Sell
89,972
-1,907
-2% -$295K 0.03% 427
2020
Q4
$14.4M Sell
91,879
-2,488
-3% -$320K 0.04% 379
2020
Q3
$10.8M Sell
94,367
-16,539
-15% -$1.78M 0.03% 407
2020
Q2
$12.4M Sell
110,906
-19,180
-15% -$2.04M 0.03% 368
2020
Q1
$11.7M Buy
130,086
+13,632
+12% +$1.34M 0.04% 367
2019
Q4
$12.6M Buy
116,454
+5,486
+5% +$587K 0.03% 415
2019
Q3
$10.9M Buy
110,968
+11,311
+11% +$1.27M 0.03% 430
2019
Q2
$13.1M Buy
99,657
+1,664
+2% +$214K 0.03% 445
2019
Q1
$13.2M Buy
97,993
+30,026
+44% +$3.73M 0.03% 441
2018
Q4
$6.67M Sell
67,967
-1,905
-3% -$225K 0.02% 522
2018
Q3
$9.71M Buy
69,872
+6,873
+11% +$862K 0.02% 492
2018
Q2
$7.82M Buy
62,999
+12,557
+25% +$1.47M 0.02% 520
2018
Q1
$5.62M Buy
50,442
+1,401
+3% +$167K 0.01% 531
2017
Q4
$5.87M Buy
49,041
+526
+1% +$64.1K 0.01% 531
2017
Q3
$6.81M Buy
+48,515
New +$6.59M 0.01% 515

Other funds holding ALXN